Cargando…

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abidi, Maheen Z., Haque, Javeria, Varma, Parvathi, Olteanu, Horatiu, Guru Murthy, Guru Subramanian, Dhakal, Binod, Hari, Parameswaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097796/ https://www.ncbi.nlm.nih.gov/pubmed/27843657 http://dx.doi.org/10.1155/2016/2389038

Ejemplares similares

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
por: Mohan, Meera, et al.
Publicado: (2022)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
por: Peng, Yizhou, et al.
Publicado: (2020)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
por: Ross, David M., et al.
Publicado: (2021)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
por: Guru Murthy, Guru Subramanian
Publicado: (2022)

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
por: Jung, Chul Won
Publicado: (2013)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
por: Li, Yujin, et al.
Publicado: (2020)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
por: Hasan, Kawa M., et al.
Publicado: (2022)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2022)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case
por: Sugiura, Hiroyuki, et al.
Publicado: (2020)

Recent advances in understanding multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2016)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n51gt5mg560dbgpfd7gtcju87a